Funding to scale-up mRNA vaccine production in SA

April 24, 2023 11:06 AM AEST | By AAPNEWS

Google News:

Funding to scale-up mRNA vaccine production in SA — Image source: AAPNEWS

Recent News

TV Anime "Jaadugar: A Witch in Mongolia" First Super Teaser Visual Rev...

AOFAR Officially Launches GX6: The Top Budget Rechargeable Golf Rangef...

CLASS ACTION AUTHORIZED AGAINST CANADA ALLEGING UNCONSTITUTIONALITY OF...

Rocket Lab Completes Record Launch Turnaround From Launch Complex 1, S...

New technology will be used to develop and produce mRNA therapeutic drugs and vaccines in Adelaide, helping to address Australia's supply issues highlighted by the COVID-19 pandemic.

Thanks to $10 million from the SA and federal governments, the BioCina pharmaceutical production facility will become an mRNA centre of excellence, to support the scale-up and production of drugs and vaccines within two years.

BioCina already produces plasmids, which are critical components of mRNA vaccines, and has a small-scale mRNA process development laboratory.

The extra cash will allow it to begin manufacturing of mRNA material to supply clinical trials, as well as scaling-up its facility to full commercial levels.

"Australia's sovereign vaccine supply problem was highlighted by COVID-19," Federal Health Minister Mark Butler said.

"This investment will ultimately build capacity to produce millions of doses of mRNA vaccines per week, adding resilience and capacity to Australia's sovereign vaccine agenda."

BioCina will work with researchers and biotech companies to develop the next generation of mRNA vaccines for diseases such as Malaria, Tuberculosis, Zika, Hepatitis B, HIV, Rabies, Influenza, Cystic Fibrosis and cancer.

That will allow it to tap into a growing market for mRNA therapeutics which is expected to grow from $46.7 billion in 2021 to $101.3 billion by 2026.

SA Health Minister Chris Picton said BioCina's mRNA facility in Adelaide would be the first in Australia to offer end-to-end client services to support the entire mRNA manufacturing and development process.

BioCina chief executive Mark Womack said the funding would increase the company's capacity to produce mRNA pharmaceuticals and bring missing clinical and commercial manufacturing capabilities.

"Projects such as this, highlight Australia's opportunity to leverage BioCina's strengths in development, manufacturing and innovation, to drive commercialisation and globally competitive local manufacturing," he said.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.